Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

IFN-beta Protein, Human, Recombinant

Catalog No. TMPY-03145

IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.

IFN-beta Protein, Human, Recombinant

IFN-beta Protein, Human, Recombinant

Catalog No. TMPY-03145
IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.
Pack SizePriceAvailabilityQuantity
20 μg$197In Stock
100 μg$4477-10 days
200 μg$7917-10 days
500 μg$1,6707-10 days
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Information

Biological Activity
Measured in antiviral assays using WISH cells infected with vesicular stomatitis virus. The ED50 for this effect is typically 2-20 pg/mL.
IFN-beta Protein, Human, Recombinant
Description
IFN-beta Protein, Human, Recombinant is expressed in CHO mammalian cells. The predicted molecular weight is 20 kDa and the accession number is P01574.
Species
Human
Expression System
CHO Cells
TagTag Free
Accession NumberP01574
Synonyms
interferon, β1, fibroblast,interferon, beta 1, fibroblast,Interferon β,Interferon beta,IFN-β,IFN-beta,IFNB,IFF,IFB
Construction
A DNA sequence encoding the human IFNβ (P01574) (Met1-Asn187) was expressed. Predicted N terminal: Met 22
Protein Purity
> 95 % as determined by SDS-PAGE
IFN-beta Protein, Human, Recombinant
Molecular Weight20 kDa (predicted); 20-23 kDa (reducing conditions)
Endotoxin< 1.0 EU/μg of the protein as determined by the LAL method.
FormulationLyophilized from a solution filtered through a 0.22 μm filter, containing 10 mM NaAC, 40 mM Arg, 0.12mg/ml Met, 146mg/ml Sucrose, 0.1% PF-68, pH 4. 5. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
Reconstitution
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
Stability & Storage
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
ShippingIn general, Lyophilized powders are shipping with blue ice.
Research Background
Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

Dose Conversion

You can also refer to dose conversion for different animals. More

Calculator

  • Reconstitution Calculator
  • Recombinant Protein Dilution Calculator
  • Specific Activity Calculator

Tech Support

Please read the User Guide of Recombinant Proteins for more specific information.

Keywords